###begin article-title 0
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 15 23 <span type="species:ncbi:9606">patients</span>
HLA-DRB1 among patients with Vogt-Koyanagi-Harada disease in Saudi Arabia
###end article-title 0
###begin p 1
The last two authors contributed equally to this work.
###end p 1
###begin title 2
Purpose
###end title 2
###begin p 3
###xml 313 316 313 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA</italic>
###xml 318 322 318 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DRB1</italic>
###xml 288 293 <span type="species:ncbi:9606">human</span>
###xml 338 346 <span type="species:ncbi:9606">patients</span>
Vogt-Koyanagi-Harada (VKH) disease is an immune-mediated disorder with autoimmune insult directed against antigens associated with melanocytes. The genetic predisposition among VKH has not been explored in Saudi Arabia. So, the purpose of this study was to investigate the association of human leukocyte antigen (HLA)-DRB1 alleles to VKH patients and to clarify the molecular genetic mechanism underlying the susceptibility or resistance to VKH disease.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 31 39 <span type="species:ncbi:9606">patients</span>
Genomic DNA from a total of 30 patients with VKH and 29 control subjects was extracted from peripheral blood, and HLA-DRB1 alleles were typed by polymerase chain reaction and sequence based typing (SBT).
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 100 108 <span type="species:ncbi:9606">patients</span>
###xml 169 177 <span type="species:ncbi:9606">patients</span>
###xml 487 495 <span type="species:ncbi:9606">patients</span>
We found a statistically significant difference in the prevalence of HLA-DRB1 *0405 between the VKH patients and control subjects (p<0.05). Eleven out of thirty (36.6%) patients with VKH had positive HLA-DRB1 *0405 compared to two out of twenty-nine (6.9%) control subjects. However, there were no statistically significant differences in the HLA-DRB1 alleles *01, *0101, *0102, *0301, *04, *0403, *0404, *0701, *1001, *1101, *1112, *1301, *1302, *1303, *1501, and *1502 between the VKH patients and controls.
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients with VKH had significantly greater incidence of HLA-DRB1 *0405 when compared to age and sex-matched controls. Consequently, this finding suggests that HLA-DRB1 *0405 allele might play a role in the pathogenesis of VKH disease.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 199 200 199 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 201 202 201 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 310 311 310 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 1451 1452 1451 1452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 489 497 <span type="species:ncbi:9606">patients</span>
###xml 766 774 <span type="species:ncbi:9606">Patients</span>
Vogt-Koyanagi-Harada (VKH) disease is a multisystem autoimmune disorder mediated by Th1 lymphocytes reacting against antigens associated with the melanocytes such as tyrosinase and related proteins [1-5]. The disease afflicts the uvea in the eye leading to chronic inflammation and may lead to loss of vision [6]. The disease occurs in stages with early involvement of the meninges followed by auditory, ocular, and integumentary structures. During the early manifestation of the disease, patients may develop malaise, fever, headache, nausea, neck stiffness, and tinnitus. Following an acute onset, the disease becomes chronic and progressive with bilateral choroiditis and panuveitis associated with nummular chorioretinal lesions or exudative retinal detachment. Patients may present with bilateral diffuse granulomatous uveitis. No cutaneous manifestations are noted during the acute phase of the disease, but alopecia, vitiligo, and poliosis may subsequently appear weeks or months after the acute onset of the disease. Tinnitus and dysacusia may occur during the initial phases of the disorder. Thus far, there are no serodiagnostic tests for this disease. and the diagnosis remains clinical. The disease presents with bilateral ocular involvement alone (probable) VKH or bilateral ocular involvement and central nervous system (CNS) and integumentary involvement (complete) VKH or with either CNS or integumentary involvement (incomplete) VKH [7].
###end p 11
###begin p 12
###xml 1053 1054 1053 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 1168 1171 1168 1171 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA</italic>
###xml 1173 1177 1173 1177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DRB1</italic>
###xml 1188 1196 1188 1196 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 1246 1247 1246 1247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 1248 1250 1248 1250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 1404 1405 1404 1405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 7 15 <span type="species:ncbi:9606">patients</span>
###xml 418 426 <span type="species:ncbi:9606">patients</span>
###xml 524 532 <span type="species:ncbi:9606">patients</span>
###xml 1143 1148 <span type="species:ncbi:9606">human</span>
###xml 1377 1385 <span type="species:ncbi:9606">patients</span>
###xml 1509 1517 <span type="species:ncbi:9606">patients</span>
In VKH patients, there is no history of penetrating ocular trauma and no clinical or laboratory evidence suggestive of other ocular disorders. In the complete form during acute onset, there is evidence of choroiditis with a focal area of subretinal fluid or bullous exudative retinal detachment. There is diffuse choroidal thickening and multifocal chorioretinal infiltrates. In the late manifestation of the disease, patients may develop sunset glow fundus, alopecia, poliosis, and vitiligo. In the incomplete form of VKH, patients show evidence of bilateral ocular involvement. There is an acute phase of malaise, fever, headache, nausea, and neck stiffness or alopecia, poliosis, or vitiligo. In the probable form of VKH, it is bilateral ocular involvement with no association of integumentary findings or neurologic findings. VKH appears to occur commonly among communities with dark pigment such as Native Americans, Middle Easterners, Asians, and Indians but not in blacks of sub-Saharan African descent. The disease is uncommon among Caucasians [7]. Increased risk among those with certain HLA genotypes showing strong association with human leukocyte antigen (HLA)-DRB1 *0405 and HLA-DRB1 *0401 have been reported in several populations [8-12]. In Saudi Arabia, VKH is a common cause of uveitis, yet there has been no previous study on the genetic predisposition among patients with VKH disease [6]. Thus, we intended to explore and analyze the frequency and the association of HLA-DRB1 alleles among patients with VKH in Saudi Arabia and to investigate its potential role in the disease manifestation.
###end p 12
###begin title 13
Methods
###end title 13
###begin title 14
Study population
###end title 14
###begin p 15
###xml 167 168 167 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 401 402 401 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 457 458 457 458 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</bold>
###xml 7 15 <span type="species:ncbi:9606">patients</span>
###xml 201 209 <span type="species:ncbi:9606">Patients</span>
###xml 352 360 <span type="species:ncbi:9606">patients</span>
###xml 405 413 <span type="species:ncbi:9606">Patients</span>
###xml 848 853 <span type="species:ncbi:9606">human</span>
###xml 915 927 <span type="species:ncbi:9606">participants</span>
Thirty patients (12 male and 18 female) with confirmed VKH as defined by the revised diagnostic criteria in the report of the International Committee on Nomenclature [7] were recruited for this study. Patients were divided into two groups, (1) complete VKH disease and (2) incomplete VKH disease, to find out whether there is any genetic difference in patients with different clinical manifestations [7]. Patients with probable VKH were not included. Twenty-nine age- and sex-matched healthy volunteers who attended the Blood Bank at King Faisal Specialist Hospital and Research Centre (KFSHRC) (Riyadh, Saudi Arabia) were included as the control. This study was approved by the King Faisal Specialist Hospital and Research Centre Institutional Review Board and maintained the strict adherence to the Declaration of Helsinki for research involving human subjects. Written informed consent was obtained from all the participants before study enrollment.
###end p 15
###begin title 16
Diagnostic criteria
###end title 16
###begin p 17
###xml 146 147 146 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients with complete or incomplete VKH were investigated in this study. The diagnosis of complete VKH disease was made as previously described [7]. The diagnosis of complete VKH when the following five criteria: (1) no history of penetrating injury or surgery; (2) no clinical or laboratory evidence suggestive of other ocular diseases; (3) bilateral ocular involvement consisting of anterior uveitis and diffuse or multifocal choroiditis with or without evidence of a retinal detachment. Late manifestations or ocular findings consist of areas of retinochoroidal depigmentations, nummular chorioretinal depigmented scar, retinal epithelial clumping, and peripapillary chorioretinal atrophy with or without chronic anterior uveitis, (4) neurologic/auditory findings include meningismus, malaise, fever, headache, stiffness of the back or neck, tinnitus or cerebrospinal fluid (CSF) pleocytosis, and (5) integumentary findings of alopecia, poliosis, and vitiligo.
###end p 17
###begin p 18
###xml 317 318 317 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
The diagnosis of incomplete VKH were made by the following criteria: (1) no history of penetrating ocular injury, (2) no clinical or laboratory evidence suggestive of other ocular disease, (3) bilateral ocular involvement, and (4) neurologic auditory findings and/or cutaneous findings such as vitiligo and poliosis [7].
###end p 18
###begin title 19
Extraction of genomic DNA
###end title 19
###begin p 20
###xml 70 72 70 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
Genomic DNA was isolated from the peripheral blood using the Puregene TM extraction Kit (Gentra Inc., Foster City, CA) following the manufacturer's recommendation. The extracted DNA was stored at -80 degreesC for long-term usage. The DNA purity and concentration was determined using a NanoDrop spectrophotometer (Thermo Scientific, Wilmington, DE).
###end p 20
###begin title 21
Determination of HLA-DRB1 allele
###end title 21
###begin p 22
The determination of the HLA-DRB1 alleles was performed by using the Allele SEQR HLA Sequencing kit with Heterozygous ambiguity resolving primers (AlleleSEQR HLA Sequencing kit+ HARPs; Atria Genetics, Inc. South San Francisco, CA). The principle of this test relies on two key technologies that are described below.
###end p 22
###begin title 23
###xml 25 33 25 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
PCR amplification of the HLA-DRB1 gene
###end title 23
###begin p 24
###xml 207 208 203 204 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
The genes of interest were amplified using 8 microl of gene-specific polymerase chain reaction (PCR) pre-mixes (gene specific oligonucleotide primer mixes in a Tris-based PCR buffer containing dNTPs and MgCl2) and 0.1 microl AmpliTaq Gold (Applied Biosystems Inc. Foster City, CA). A total of 40 ng of genomic DNA was added, and the volume was finally adjusted to 10 microl with sterile water. Amplification of the gene was done on PCR thermal cycler (MJ Research,GMI, Ramsay, Minnesota). PCR was initiated with an initial denaturation at 95 degreesC for 10 min followed by amplification of 36 cycles at 96 degreesC for 20 s, 60 degreesC for 30 s , and finally 72 degreesC for 3 min. This was followed by cleaning of the amplified product using ExoSAP-IT (Exonuclease I and Shrimp Alkaline Phosphatase, together in a specially formulated buffer) from Usb Corporation (Cleveland, OH) and was stored for future use.
###end p 24
###begin title 25
###xml 14 22 14 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
Sequencing of HLA-DRB1 alleles
###end title 25
###begin p 26
The amplified product serves as a DNA sequencing template in the reaction. Eight microliters of sequencing mix was dispensed in separate reaction tubes with 2 microl of the ExoSAP-treated PCR product. The thermal condition for the sequencing reaction was as follows: 25 cycles for 20 s at 96 degreesC, 30 s at 50 degreesC, and 2 min at 60 degreesC. Finally, the sequence reaction was purified using DyeEx 2.0 spin kit (Qiagen Inc. Valencia, CA) and then suspended with Hi Di Formamide (Applied Biosystems, Foster city,CA) to run on the 3130xl Genetic Analyzer (Applied Biosystems).
###end p 26
###begin title 27
Statistical analysis
###end title 27
###begin p 28
###xml 55 63 55 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 142 150 142 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 81 89 <span type="species:ncbi:9606">patients</span>
This is a case-control study in which the frequency of HLA-DRB1 alleles in Saudi patients with VKH disease was compared with the frequency of HLA-DRB1 alleles in a similar group of Saudis without the VKH disease (controls). The risk of the disease was estimated by the odds ratio and calculation of the 95% confidence interval of the odds ratio. A p-value of less than 0.05 was considered significant.
###end p 28
###begin title 29
Results
###end title 29
###begin p 30
###xml 14 22 <span type="species:ncbi:9606">patients</span>
###xml 186 194 <span type="species:ncbi:9606">patients</span>
###xml 220 228 <span type="species:ncbi:9606">patients</span>
###xml 349 357 <span type="species:ncbi:9606">patients</span>
A total of 30 patients with VKH from the Eye Center and the Eye Foundation for Research in Ophthalmology (Riyadh, Saudi Arabia) were recruited during the period 2007-2008. There were 15 patients with complete VKH and 15 patients with incomplete VKH. A total of 29 healthy volunteer subjects were included. The healthy volunteers were not related to patients with VKH or to each other and were of the same ethnic origin.
###end p 30
###begin p 31
###xml 0 7 0 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 43 51 43 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 144 152 144 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 232 240 232 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 264 272 264 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 384 392 384 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 403 412 403 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA- DRB1</italic>
###xml 623 631 623 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 894 901 894 901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 953 961 953 961 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 1016 1024 1016 1024 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 1182 1190 1182 1190 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 1277 1285 1277 1285 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DBR1</italic>
###xml 1352 1360 1352 1360 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 1477 1485 1477 1485 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 1606 1613 1606 1613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 68 76 <span type="species:ncbi:9606">patients</span>
###xml 177 185 <span type="species:ncbi:9606">patients</span>
###xml 568 576 <span type="species:ncbi:9606">patients</span>
###xml 737 745 <span type="species:ncbi:9606">patients</span>
###xml 1140 1148 <span type="species:ncbi:9606">patients</span>
###xml 1373 1381 <span type="species:ncbi:9606">patients</span>
Table 1 summarizes the gene frequencies of HLA-DRB1 alleles for VKH patients and the control group. No significant differences were observed in HLA-DRB1 frequencies between the patients with VKH and control group. However, when the HLA-DRB1 *04 were subtyped, the HLA-DRB1 *0405 allele was found to be positively associated with VKH in the Saudi population (p=0.01). The frequency of HLA-DRB1 *0401 and HLA- DRB1 *0410 were measured to be very low in the normal Saudi population (unpublished). Accordingly, these alleles were not detected in our study population (VKH patients and matched controls). On the other hand, the HLA-DRB1 *0301 and *0403 alleles were found to be higher in the control group than what have been observed in the patients with VKH despite achieving statistically insignificant association, indicating a possible protective role of these two alleles against the disease (Table 1). To assess the significance of the association of HLA-DRB1 *0405 alleles and the VKH disease, the association of HLA-DRB1 *0405 with complete VKH and incomplete VKH was analyzed. Five out of fifteen cases of complete VKH and 6 out of 15 patients with incomplete VKH had positive HLA-DRB1 *0405 with no statistically significant difference (data not shown). The frequency of HLA-DBR1 *0701 allele was found to be the highest among all the alleles of HLA-DRB1 in both VKH patients and controls. On the other hand, no statistically significant differences were detected in the HLA-DRB1 alleles *01, *0101, *0102, *0301, *04, *0403, *0404, *0701, *1001, *1101, *1112, *1301, *1302, *1303, *1501, and *1502 (Table 1).
###end p 31
###begin title 32
###xml 43 51 <span type="species:ncbi:9606">patients</span>
Allele frequencies of the HLA- DRB1 in VKH patients and in controls.
###end title 32
###begin p 33
###xml 18 26 18 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 53 61 <span type="species:ncbi:9606">patients</span>
Table 1 shows the HLA-DRB1 allele frequencies in VKH patients and controls. The bold numbers in the table indicates allele *0405, showing a significant p value. Abbreviations in the table are, OD; Odds Ratio, CI; Confidence Interval.
###end p 33
###begin title 34
Discussion
###end title 34
###begin p 35
###xml 19 27 19 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 103 104 103 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 105 107 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 108 110 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 298 306 298 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 333 341 333 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 434 442 434 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 561 569 561 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 621 623 621 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 689 690 689 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 941 942 941 942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 943 944 943 944 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 945 946 945 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 1089 1090 1089 1090 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 1305 1307 1305 1307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 1544 1546 1544 1546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 1686 1688 1686 1688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 1807 1815 1807 1815 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 1899 1900 1899 1900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 1901 1902 1901 1902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 1903 1905 1903 1905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 1906 1908 1906 1908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 1909 1911 1909 1911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
###xml 2029 2030 2029 2030 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 2031 2033 2031 2033 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 2088 2096 2088 2096 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 2213 2214 2213 2214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 2215 2217 2215 2217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 2231 2239 2231 2239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 2254 2262 2254 2262 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 2321 2323 2321 2323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 2345 2353 2345 2353 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 2488 2496 2488 2496 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 2652 2654 2652 2654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 2676 2684 2676 2684 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 3154 3162 3154 3162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 3199 3201 3199 3201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
###xml 3453 3461 3453 3461 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DQA1</italic>
###xml 3554 3562 3554 3562 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DQA1</italic>
###xml 3584 3586 3584 3586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 3692 3701 3692 3701 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA- DRB1</italic>
###xml 3716 3724 3716 3724 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DQB1</italic>
###xml 3751 3752 3751 3752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 3784 3792 3784 3792 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 3806 3814 3806 3814 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 3905 3913 3905 3913 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 3928 3936 3928 3936 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 4076 4084 4076 4084 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 4095 4103 4095 4103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 4111 4112 4111 4112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 4113 4115 4113 4115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 4252 4261 4252 4261 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA- DRB1</italic>
###xml 4272 4280 4272 4280 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 4419 4427 4419 4427 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 4455 4463 4455 4463 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 611 619 <span type="species:ncbi:9606">patients</span>
###xml 1283 1288 <span type="species:ncbi:9606">human</span>
###xml 1476 1494 <span type="species:ncbi:10376">Epstein-Barr virus</span>
###xml 1636 1644 <span type="species:ncbi:9606">patients</span>
###xml 1753 1760 <span type="species:ncbi:9606">patient</span>
###xml 1851 1859 <span type="species:ncbi:9606">patients</span>
###xml 2116 2124 <span type="species:ncbi:9606">patients</span>
###xml 2376 2384 <span type="species:ncbi:9606">patients</span>
###xml 2528 2536 <span type="species:ncbi:9606">patients</span>
###xml 2826 2834 <span type="species:ncbi:9606">patients</span>
###xml 3068 3076 <span type="species:ncbi:9606">patients</span>
###xml 3426 3434 <span type="species:ncbi:9606">patients</span>
###xml 3832 3840 <span type="species:ncbi:9606">patients</span>
###xml 3879 3887 <span type="species:ncbi:9606">patients</span>
###xml 4197 4205 <span type="species:ncbi:9606">patients</span>
###xml 4375 4383 <span type="species:ncbi:9606">patients</span>
Association of the HLA-DRB1 *0405 allele and VKH disease has already been reported in the other races [8,11,12]. However, this is the first report studying the genetic predisposition of a very important autoimmune disease, Vogt-Koyanagi-Harada Disease (VKH), in Saudi Arabia. We performed complete HLA-DRB1 genotyping and found that HLA-DRB1 *0405 was significantly associated with VKH disease, and no such association was noted with HLA-DRB1 *0404. The association between class I antigen and VKH disease may differ among various ethnic groups. Among Koreans, HLA-DRB1 *04 was positive in 17 (94.4%) out of 18 patients [11]. Although the clinical manifestations of VKH are well outlined [7], the exact etiology of this condition remains to be elucidated. It has been suggested the mechanism could be a T-lymphocyte-mediated autoimmune process directed against an unidentified antigen or a group of antigens associated with the melanocytes [1,4,5]. Although the mechanism that triggers this autoimmune attack against melanocytes is unknown, sensitization to melanocytes has been proposed [5]. While the exact target antigen has not been identified, several candidates were proposed. This includes tyrosinase or tyrosinase-related proteins and a 75 kDa protein obtained from cultured human melanoma cells [13]. The etiology of VKH syndrome is not certain, but the clinical history of VKH syndrome mimics an influenza attack, which implies a viral or post infectious origin. An Epstein-Barr virus reactivation in this disease has been suggested [14]. Although a viral cause has been projected, no virus has been isolated or cultured from patients with VKH syndrome. Morris and Schlaegel [15] found virus-like inclusion bodies in the subretinal fluid of a patient with the VKH syndrome. An association between HLA-DRB1 *0405 and VKH has been noted among patients from Japan, Brazil, Korea, and Mexico [8,9,11,12,16]. Therefore, a genetically determined susceptibility to the triggering event for the VKH disease has been suggested [5,17]. The data presented here confirmed an association of HLA-DRB1 *0405 with the VKH patients in Saudi Arabia. This relationship was similar to those reported from Japan and Brazil [8,12]. Out of the HLA-DRB1 *04 subtypes, HLA-DRB1 *0405 had the strongest association with the VKH disease [11]. The association of HLA-DRB1 *0405 among Brazilian patients with VKH may reflect a genetic pool inherited from Japanese descendants. Kim and associates found that HLA-DRB1 *0405 was greatly increased in patients with VKH syndrome among Koreans and might have an important role in the development of the clinical course of VKH [11]. On the other hand, HLA-DRB1 alleles such as *0705, *1001, *1101, *1112,*1301, *1302, *1303, *1501, and *1502 showed no statistically significant differences between VKH patients and controls. Genetic predisposition and environmental triggers may play a role in the pathogenesis of VKH in Saudi Arabia. Alternatively, the diagnostic criteria of the VKH disease were revised recently in a cohort of VKH Brazilian patients wherein no association was found between disease categories, the presence of HLA-DRB1 *0405, and the clinical parameters [16]. We think that differences in the genetic background in different geographical areas might contribute to these discrepancies and that more studies need to be done before the previous statement can be generalized. In Korean patients with VKH disease, HLA-DQA1 *0301 was less frequently detected than in normal control subjects whereas the frequency of HLA-DQA1 *0302 was increased [11]. These findings suggest that gene association with VKH disease in the HLA region is located between the HLA- DRB1 locus and the HLA-DQB1 locus. Shindo and others [8] have reported the presence of HLA-DRB1 *0405 and/or HLA-DRB1 *0410 in the VKH patients. Moreover, they reported that the VKH patients who did not have HLA-DRB1 *0405 possess HLA-DRB1 *0410 alleles, suggesting that the susceptibility to VKH disease was determined by the presence of the shared functional epitope common to HLA-DRB1 *0405 and HLA-DRB1 *0410 [8,18]. But, these alleles were not detected in our study population in either the VKH patients or their matched controls as the frequency of HLA- DRB1 *0401 and HLA-DRB1 *0410 were measured to be very low in the normal Saudi population (unpublished). To conclude, patients with VKH had a higher incidence of HLA-DRB1 *0405, indicating that the HLA-DRB1 *0405 allele might play a role in the pathogenesis of VKH disease.
###end p 35
###begin title 36
Acknowledgments
###end title 36
###begin p 37
This study was funded by the Research Advisory Council at the King Faisal Specialist Hospital and Research Centre (Riyadh, Saudi Arabia) with the RAC no. 20. Drs. K.F. Tabbara and K. Al Hussein contributed equally to the research project and can be considered co-corresponding authors.
###end p 37
###begin title 38
References
###end title 38
###begin article-title 39
###xml 94 102 <span type="species:ncbi:9606">patients</span>
Melanocyte lysis by cytotoxic T lymphocytes recognizing the MART-1 melanoma antigen in HLA-A2 patients with Vogt-Koyanagi-Harada disease.
###end article-title 39
###begin article-title 40
The role of cytotoxic T lymphocytes in the pathogenesis of Vogt-Koyanagi-Harada disease.
###end article-title 40
###begin article-title 41
###xml 41 49 <span type="species:ncbi:9606">patients</span>
Humoral and cellular immunity studies in patients with Vogt-Koyanagi-Harada syndrome and pars planitis.
###end article-title 41
###begin article-title 42
Melanoma specific Th1 cytotoxic T lymphocyte lines in Vogt-Koyanagi-Harada disease.
###end article-title 42
###begin article-title 43
###xml 74 82 <span type="species:ncbi:9606">patients</span>
T-cell recognition and cytokine profile induced by melanocyte epitopes in patients with HLA-DRB1*0405-positive and -negative Vogt-Koyanagi-Harada uveitis.
###end article-title 43
###begin article-title 44
###xml 33 41 <span type="species:ncbi:9606">children</span>
Vogt-Koyanagi-Harada syndrome in children compared to adults.
###end article-title 44
###begin article-title 45
Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature.
###end article-title 45
###begin article-title 46
HLA-DRB1 typing of Vogt-Koyanagi-Harada's disease by PCR-RFLP and the strong association with DRB1*0405 and DRB1*0410.
###end article-title 46
###begin article-title 47
###xml 38 46 <span type="species:ncbi:9606">patients</span>
HLA-DRB1 and -DQB1 alleles in mestizo patients with Vogt-Koyanagi-Harada's disease in Southern California.
###end article-title 47
###begin article-title 48
###xml 60 68 <span type="species:ncbi:9606">patients</span>
HLA typing in Vogt-Koyanagi-Harada syndrome in North Indian patients.
###end article-title 48
###begin article-title 49
Association of HLA with Vogt-Koyanagi-Harada syndrome in Koreans.
###end article-title 49
###begin article-title 50
###xml 53 61 <span type="species:ncbi:9606">patients</span>
HLA-DRB1*0405 is the predominant allele in Brazilian patients with Vogt-Koyanagi-Harada disease.
###end article-title 50
###begin article-title 51
###xml 70 78 <span type="species:ncbi:9606">patients</span>
Frequent immune response to a melanocyte specific protein KU-MEL-1 in patients with Vogt-Koyanagi-Harada disease.
###end article-title 51
###begin article-title 52
###xml 0 18 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Epstein-Barr virus-related antibody pattern in uveitis.
###end article-title 52
###begin article-title 53
Viruslike Inclusion Bodies in Subretinal Fluid in Uveo-Encephalitis.
###end article-title 53
###begin article-title 54
Revised diagnostic criteria for vogt-koyanagi-harada disease: considerations on the different disease categories.
###end article-title 54
###begin article-title 55
In silico prediction of binding of putative antigenic peptides to HLA-DRB1 alleles in Vogt-Koyanagi-Harada disease.
###end article-title 55
###begin article-title 56
Complete association of the HLA-DRB1*04 and -DQB1*04 alleles with Vogt-Koyanagi-Harada's disease.
###end article-title 56

